Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - adjuvant


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8503
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

David J. Kwiatkowski · Valerie W. Rusch · Jamie E. Chaft · Bruce E. Johnson · Alan Nicholas · Ignacio Ivan Wistuba · Robert E. Merritt · Jay M. Lee · Paul A. Bunn · Yan Tang · See-Chun Phan · Saiama N. Waqar · Alexander Patterson · Eric B. Haura · Eric M. Toloza · Karen L. Reckamp · Dan J. Raz · Katja Schulze · Ann M. Johnson · David P. Carbone ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.18.02309
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Yanhong Deng · Pan Chi · Ping Lan · Lei Wang · Weiqing Chen · Long Cui · Daoda Chen · Jie Cao · Hongbo Wei · Xiang Peng · Zonghai Huang · Guanfu Cai · Ren Zhao · Zhongcheng Huang · Lin Xu · Hongfeng Zhou · Yisheng Wei · Hao Zhang · Jian Zheng · Yan Huang · Zhiyang Zhou · Yue Cai · Liang Kang · Meijin Huang · Xiaojian Wu · Junsheng Peng · Donglin Ren · Jianping Wang ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.502
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

Otto Metzger Filho · Giuseppe Viale · Lorenzo Trippa · Tianyu Li · Denise A. Yardley · Ingrid A. Mayer · Vandana G. Abramson · Carlos L. Arteaga · Laura Spring · Adrienne G. Waks · Michalina Janiszewska · Eileen Wrabel · Michelle Demeo · Aditya Bardia · Tari A. King · Kornelia Polyak · Eric P. Winer · Ian E. Krop ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.3501
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson · Alberto Sobrero · Takayuki Yoshino · Ioannis Sougklakos · Fang-Shu Ou · Jeffery P. Meyers · Qian Shi · Mark P Saunders · Roberto Labianca · Takeharu Yamanaka · Ioannis Boukovinas · Niels Henrik Hollander · Valter Torri · Kentaro Yamazaki · Vassilis Georgoulias · Sara Lonardi · Andrea Harkin · Gerardo Rosati · James Paul ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9504
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

Ahmad A. Tarhini · Sandra J. Lee · F. Stephen Hodi · Uma N. M. Rao · Gary I. Cohen · Omid Hamid · Laura F. Hutchins · Jeffrey A. Sosman · Harriet M. Kluger · Vernon K. Sondak · Henry B. Koon · Donald P. Lawrence · Kari Kendra · David R. Minor · Carrie B. Lee · Mark R. Albertini · Lawrence E. Flaherty · Teresa M. Petrella · John M. Kirkwood ·

Medicine
PDF

Given the low‐quality evidence observed in this scoping review for adjuvant treatments, the implication for practice is that current management guidelines be followed.

Adjuvant therapies in venous leg ulcer management: A scoping review [10.1111/wrr.12724]


L-theanine is an amino acid naturally found in green tea (Camellia sinensis) and some other plant extracts, and recent clinical studies have proposed promising adjuvant effects of L-theanine for the negative impact of anxiety and psychological stress on health.

Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia. [10.1016/j.phrs.2019.104395]


A total of 184 patients (HER2 33%, TNBC 27%), with a mean follow-up time of 4 years, treated with neoadjuvant systemic therapy (92% anthracycline-taxane based) were analyzed revealing 43 events (38 recurrences, 28 deaths).

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy [10.1245/s10434-019-07741-w]


CONCLUSION The intranasal influenza vaccine adjuvanted with LTh(αK) is generally safe and could provide systemic and local antibody responses.

A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(αK): A phase II study. [10.1016/j.vaccine.2019.11.047]


▶ Bemerkenswert ist, mit welcher Schnelligkeit sich die Dreifachkombination ohne direkten Vergleich zu dem derzeit gängigen Standard Gemcitabin/Capecitabin als Therapie der ersten Wahl in der adjuvanten Situation durchgesetzt hat.

FOLFIRINOX nach Resektion von Pankreaskarzinomen setzt neue Maßstäbe [10.1007/s15004-019-6706-7]


Highly Related Keywords from adjuvant

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals